Patents by Inventor Sheng-Bin Peng

Sheng-Bin Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS G12C INHIBITOR DOSING REGIMENS
    Publication number: 20240108618
    Abstract: Disclosed herein are dosing regimens for the administration of a compound of Formula I: or pharmaceutically acceptable salt thereof, or in combination with one or more of a second therapeutic agent, to a patient in need of such treatment.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 4, 2024
    Inventors: David Michael HYMAN, Xueqian GONG, Sheng-Bin PENG, Chong SI, Melinda Dale WILLARD
  • KRAS G12C INHIBITORS
    Publication number: 20240025916
    Abstract: The present disclosure provides compounds of the formula: where R1, R2, R3, R4, R5, A, and B are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: November 24, 2021
    Publication date: January 25, 2024
    Inventors: David Michael HYMAN, Gregory Lawrence LACKNER, Sheng-Bin PENG, Bree Leigh RICHEY, Chong SI
  • KRAS Gl2C INHIBITORS
    Publication number: 20230339968
    Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 26, 2023
    Inventors: Serge Louis BOULET, Kevin Charles FORTNER, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
  • KRas G12C inhibitors
    Patent number: 11731984
    Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Eli LIlly and Company
    Inventors: Serge Louis Boulet, Kevin Charles Fortner, Deqi Guo, David Michael Hyman, Sheng-Bin Peng, Chong Si
  • KRAS G12C INHIBITORS
    Publication number: 20210179633
    Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 17, 2021
    Inventors: Serge Louis BOULET, Kevin Charles FORTNER, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
  • KRas G12C inhibitors
    Patent number: 10968214
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 6, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, David Andrew Coates, Ryan James Linder, Sheng-Bin Peng, Mohammad Sadegh Zia-Ebrahimi
  • KRAS G12C INHIBITORS
    Publication number: 20200115375
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventors: David Anthony BARDA, David Andrew COATES, Ryan James LINDER, Sheng-Bin PENG, Mohammad Sadegh ZIA-EBRAHIMI
  • RAF inhibitor compounds
    Patent number: 9334267
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: May 10, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Raf inhibitor compounds
    Patent number: 9187474
    Abstract: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 17, 2015
    Assignees: Deciphera Pharmaceuticals, LLC, Eli Lilly and Company
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, Timothy Malcolm Caldwell, William C. Patt, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • RAF INHIBITOR COMPOUNDS
    Publication number: 20150119392
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 30, 2015
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • RAF INHIBITOR COMPOUNDS
    Publication number: 20150105367
    Abstract: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 16, 2015
    Inventors: Daniel L. Flynn, Michael D, Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, Timothy Malcolm Caldwell, William C. Patt, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Anti-CXCR4 antibodies
    Patent number: 8003102
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: August 23, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • ANTI-CXCR4 ANTIBODIES
    Publication number: 20110086027
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: December 17, 2010
    Publication date: April 14, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Anti-CXCR4 antibodies
    Patent number: 7892546
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: February 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • ANTI-CXCR4 ANTIBODIES
    Publication number: 20100285005
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: May 7, 2009
    Publication date: November 11, 2010
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • CYCLIC PEPTIDE CXCR4 ANTAGONISTS
    Publication number: 20100130409
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Application
    Filed: January 25, 2010
    Publication date: May 27, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Cyclic peptide CXCR4 antagonists
    Patent number: 7691813
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: April 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • CYCLIC PEPTIDE CXCR4 ANTAGONISTS
    Publication number: 20080300177
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Application
    Filed: May 20, 2008
    Publication date: December 4, 2008
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Lipoglycopeptide antibiotics
    Patent number: 6951840
    Abstract: Provided are novel lipoglycopeptides exhibiting bacterial signal peptidase inhibitory activity. Also provided are actinomycete strains that produce these lipoglycopeptides, methods of producing such lipoglycopeptides by culturing these strains, pharmaceutical compositions comprising these lipoglycopeptides, and methods of treating bacterial infections comprising contacting bacteria susceptible to treatment with the present bacterial signal peptidase inhibitor lipoglycopeptides. These lipoglycopeptides are useful in human and veterinary medicine.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: October 4, 2005
    Assignee: Eli Lilly and Company
    Inventors: Matthew David Belvo, Adam Joseph Kreuzman, Palaniappan Kulanthaivel, Sheng-Bin Peng, Tim Allen Smitka
  • Cyclic peptide CXCR4 antagonists
    Patent number: RE42274
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: April 5, 2011
    Assignee: Eli Lilly and Company
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan